What Dash Bio does
Dash Bio operates an automated bioanalysis platform that combines AI, robotics and proprietary software to run assays such as ELISA, MSD and LC-MS for pharmaceutical and biotech companies developing new drugs. The company says its 24,000-square-foot lab can deliver results in days rather than the months traditional bioanalytical labs typically take, and it only charges customers once an assay is validated to meet their requirements. Dash Bio was founded in 2024 and is based in Boston.
Dash Bio is a research tool on Falcoscan. AI and robotics platform that runs bioanalytical testing for drug developers in days, not months. Falcoscan rates Dash Bio with an Opportunity score of 78/100, a Saturation score of 14/100, and a Wrapper-risk score of 15/100. Market signal: hot. Dash Bio is founded in 2024, currently at Series_a stage. Pricing: Paid.